Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition.
Date
2022-07-11Author
Beykou, M
Arias-Garcia, M
Roumeliotis, TI
Choudhary, JS
Moser, N
Georgiou, P
Bakal, C
Type
Journal Article
Metadata
Show full item recordAbstract
When used in combination with hormone treatment, Palbociclib prolongs progression-free survival of patients with hormone receptor positive breast cancer. Mechanistically, Palbociclib inhibits CDK4/6 activity but the basis for differing sensitivity of cancer to Palbociclib is poorly understood. A common observation in a subset of Triple Negative Breast Cancers (TNBCs) is that prolonged CDK4/6 inhibition can engage a senescence-like state where cells exit the cell cycle, whilst, remaining metabolically active. To better understand the senescence-like cell state which arises after Palbociclib treatment we used mass spectrometry to quantify the proteome, phosphoproteome, and secretome of Palbociclib-treated MDA-MB-231 TNBC cells. We observed altered levels of cell cycle regulators, immune response, and key senescence markers upon Palbociclib treatment. These datasets provide a starting point for the derivation of biomarkers which could inform the future use CDK4/6 inhibitors in TNBC subtypes and guide the development of potential combination therapies.
Collections
Subject
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6
Female
Humans
Proteome
Proteomics
Triple Negative Breast Neoplasms
Research team
Prote & Metabolomics Fac
Dynamical Cell Systems
Language
eng
Date accepted
2022-06-28
License start date
2022-07-11
Citation
Scientific Data, 2022, 9 (1), pp. 395 -
Publisher
NATURE PORTFOLIO